Skip to main content
. Author manuscript; available in PMC: 2018 Jan 31.
Published in final edited form as: J Peripher Nerv Syst. 2012 Mar;17(1):53–61. doi: 10.1111/j.1529-8027.2012.00375.x

Figure 1.

Figure 1

Natural history of neuromuscular weakness in SAPP. This figure shows the mean neuromuscular severity scores (NMSS) from a cohort of 77 B7-2 knockout (B7-2 KO) and 31 B7-2 wild-type (B7-2 WT) female NOD mice. There is progressive weakness in B7-2 KO mice (red lines), with the most rapid progression seen from 20 to 24 weeks of age. There is gradual progression in weakness reaching a plateau by 31 weeks, with slight worsening seen after 38 weeks of age in this cohort. Based on NMSS, SAPP can be divided into a disease onset phase (20–24 weeks), early progressive phase (25–30 weeks), plateau (31–37 weeks), and late progressive phase (>38 weeks). Weakness is also observed in age-controlled B7-2 WT female mice affected with diabetes (blue lines) in an “all-or-none” fashion (resulting in wider error bars) that reached a plateau by 27 weeks of age. Few B7-2 WT mice survived after 30 weeks of age, resulting in wider variations in mean NMSS between 29 and 39 weeks of age. B7-2 KO mice are weaker than WT controls from ages 20–40 weeks. * indicates p < 0.05 comparing age-matched B7-2 KO and B7-2 WT mice, # indicates p < 0.05 between 27 weeks (early progressive) and 31 weeks (plateau) in SAPP, and ^ indicates p < 0.05 between 31 weeks (plateau) and late progressive phase (38 weeks).